Carl J. St. Bernard Appointed President and CEO of CeloNova

Friday, February 26, 2021

CeloNova BioSciences, Inc. today announced appointment of seasoned medical device executive Carl J. St. Bernard as President and Chief Executive Officer to support the company’s expected near-term commercial growth.

St. Bernard joins the company from Tryton Medical where he held the role of President and CEO, leading the company’s commercialization efforts in the highly competitive coronary stent market. St. Bernard also has an extensive track record growing businesses across a variety of fields including pharmaceuticals, consumer health products and diagnostic markets. St. Bernard’s prior experience includes Vice President at Johnson & Johnson Vision (formerly Abbott Medical Optics), Vice President of North American Marketing & Sales for LifeCell and Vice President at Cordis where he led the commercial operations for the cardiovascular and endovascular businesses in the U.S.

Jason Cone, who successfully served as CeloNova’s interim CEO for the past 2 years, will assume a position on the company’s Board of Directors. Under his leadership the company accomplished key commercial milestones and reached over 25,000 patients treated worldwide.

“Carl’s strong track record of commercial success and deep understanding of our customer’s needs is a huge asset as we broaden clinical adoption of COBRA PzF NCS across practices treating high-risk patients unable to tolerate long-term DAPT,” stated Mark Bates, MD, DSC, FACC, FSCAI, Director of the CAMC Cardiovascular Medicine Fellowship and Senior Scientist for Cardiovascular Research and Chairman of the Board at CeloNova. “We look forward to working with Carl to bring innovative cardiovascular treatments to patients around the world.”

The appointment of St. Bernard precedes the highly anticipated conclusion of the company’s COBRA REDUCE study, the world’s first and only randomized global trial evaluating ultra-short, 14-day dual-antiplatelet therapy (DAPT) compared to market-leading drug-eluting stents with 3 or 6 months DAPT in patients at high risk of bleeding.§^

Today, COBRA PzF NCS allows physicians to safely and effectively treat patients who may benefit from short, 1-month DAPT.1,2 In the PzF SHIELD IDE trial, COBRA PzF NCS with 1-month DAPT demonstrated 0% stent thrombosis, 4.6% total lesion revascularization at 9 month follow up.1,2 Low TLR and low ST with short DAPT has been consistently demonstrated across CeloNova’s comprehensive clinical trial program.3

“PCI patients at high risk for bleeding complications have long been a challenge for the interventional cardiology community,” stated St. Bernard. “COBRA PzF NCS is an innovative solution, unlike any other in the coronary stent market, that offers a safe and effective option for these patients. I look forward to leading CeloNova into its next phase of commercial growth.”

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc.